Skip to content
Screener

Travere Therapeutics, Inc. TVTX EV / EBITDA

EV / EBITDA at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
22.4×—
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
525.2×—
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
7.7×-10.6×
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
7.9×—
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
4.6×—

Other financials

Income statement

See full
Revenue$127.2M+55.6%
Gross profit$125.2M+62.5%
Operating income-$36.9M+13.5%
Net income-$37.1M+10.0%
EPS (diluted)-$0.40+14.9%

Balance sheet

See full
Cash & equivalents$78.4M+26.6%
Total debt$15.6M-82.6%
Total equity$98.7M+201%
Total assets$555.2M+1.2%

Cash flow

See full
Operating cash flow-$40.4M+4.3%
CapEx$140.0K—
Free cash flow-$42.5M+28.1%

Valuation

See full
Market cap$5.89B+284%
Enterprise value$5.82B+277%
P/S11×+6.4×

Profitability

See full
Gross margin98.6%+2.6pp
Operating margin-10.6%-5.0pp
Net margin-20.3%-9.5pp
FCF margin-133.9%-34.4pp

Returns & leverage

See full
Return on equity-706%-1,302pp
Debt / equity0.2×-2.6×
Current ratio3.1×+1.1×

Where this comes from

Calculated from Travere Therapeutics, Inc.’s reported figures.

enterprise value/ebitda=166.4×

Based on the most recent quarter.

The source filing: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026. Open the filing →

Filed
May 4, 2026, 4:45 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001438533-26-000042

FAQ

What is Travere Therapeutics, Inc.'s EV / EBITDA?
Travere Therapeutics, Inc. (TVTX) reported EV / EBITDA of 166.4× in Q1 2026.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.

Ask your AI about Travere Therapeutics, Inc.'s ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude